Cargando…
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
BACKGROUND: The effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to determine whether COVID-19 vaccine-induced antibody responses were altered in patients with IBD on commonly used immunosuppr...
Autores principales: | Alexander, James L, Kennedy, Nicholas A, Ibraheim, Hajir, Anandabaskaran, Sulak, Saifuddin, Aamir, Castro Seoane, Rocio, Liu, Zhigang, Nice, Rachel, Bewshea, Claire, D'Mello, Andrea, Constable, Laura, Jones, Gareth R, Balarajah, Sharmili, Fiorentino, Francesca, Sebastian, Shaji, Irving, Peter M, Hicks, Lucy C, Williams, Horace R T, Kent, Alexandra J, Linger, Rachel, Parkes, Miles, Kok, Klaartje, Patel, Kamal V, Teare, Julian P, Altmann, Daniel M, Boyton, Rosemary J, Goodhand, James R, Hart, Ailsa L, Lees, Charlie W, Ahmad, Tariq, Powell, Nick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813209/ https://www.ncbi.nlm.nih.gov/pubmed/35123676 http://dx.doi.org/10.1016/S2468-1253(22)00005-X |
Ejemplares similares
-
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
por: Alexander, James L, et al.
Publicado: (2022) -
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
por: Liu, Zhigang, et al.
Publicado: (2023) -
Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022) -
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
por: Liu, Zhigang, et al.
Publicado: (2023) -
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
por: Alexander, James L., et al.
Publicado: (2023)